These innovative compounds represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://albertqozh843159.develop-blog.com/46818235/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide